Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Massimiliano Mazza

Massimiliano Mazza

PhD
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)
Strategies being explored to enhance the efficacy of CAR T-cells in hematological malignancies 5:04
Strategies being explored to enhance the efficacy of CAR T-cells in hematological malignancies
Massimiliano Mazza • 26 Feb 2025
The challenges associated with developing CAR-T products for T-cell malignancies 3:00
The challenges associated with developing CAR-T products for T-cell malignancies
Massimiliano Mazza • 26 Feb 2025
The development of a novel TRBC1-directed CAR T-cell therapy for T-cell malignancies 2:27
The development of a novel TRBC1-directed CAR T-cell therapy for T-cell malignancies
Massimiliano Mazza • 26 Feb 2025
Insights into the ‘Alleanza Contro il Cancro’ and its CAR-T project 2:22
Insights into the ‘Alleanza Contro il Cancro’ and its CAR-T project
Massimiliano Mazza • 25 Oct 2022
Exciting research in the CAR-T space: the promise of allogeneic therapies 1:20
Exciting research in the CAR-T space: the promise of allogeneic therapies
Massimiliano Mazza • 25 Oct 2022
The content of VJHemOnc is intended for healthcare professionals